Abstract Details

Title Feasibility of Digital Health and Wearable Technology Interventions for Secondary Stroke Prevention

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P3 - Poster Session 3 (5:00 PM-6:00 PM)

Poster/Presentation
Number 5-012

Objective To evaluate the feasibility, usability, and patient engagement of digital health and wearable interventions for secondary prevention among stroke survivors.

Background Digital health interventions, including mobile applications, telehealth services, and wearable sensors, have emerged as promising tools to support risk factor management after stroke. However, implementation challenges are not well characterized.

Design/Methods A systematic review of MEDLINE, Embase, and CENTRAL (inception to September 2025) identified studies involving adults with prior stroke or transient ischemic attack using digital or wearable tools for secondary prevention. Feasibility outcomes included recruitment, retention, device use adherence, and patient/provider satisfaction.

Results Nine studies (n=318 participants; mean age 59 years; 41% women), including three feasibility-only pilots, reported usability data. Average completion was 84% (CI: 77-89%), and device adherence ranged from 60-90%. Overall attrition was 14% (95% CI 9–21%). Common barriers included device setup complexity, Bluetooth connectivity issues, cognitive/visual deficits, and alert fatigue. Facilitators of sustained engagement included simplified user interfaces, caregiver involvement, brief check-ins, and closed-loop workflows with nurse/pharmacist follow-up. Programs with defined escalation protocols achieved higher sustained engagement (median follow-up 3 months [range 2–9]). Across studies, patient satisfaction and perceived usefulness were high, though engagement declined over time without reinforcement.

Conclusions Digital secondary-prevention programs are feasible after stroke when paired with reliable onboarding, accessibility support, and timely human feedback. Addressing usability and workflow barriers is critical to sustaining participation and scaling these tools in secondary prevention programs.

Authors/Disclosures
Shervin Badihian, MD (Cleveland Clinic) PRESENTER	Dr. Badihian has nothing to disclose.
Bradley G. Ong, MD (Cleveland Clinic Main Campus - Neurological Institute)	The institution of Dr. Ong has received research support from American Academy of Neurology. The institution of Dr. Ong has received research support from American Headache Society. Dr. Ong has received personal compensation in the range of $0-$499 for serving as a Expert Witness with Chandler Advocacy. Dr. Ong has a non-compensated relationship as a Editorial Board Member with Neurology Resident & Fellow Section that is relevant to AAN interests or activities. Dr. Ong has a non-compensated relationship as a Contributor with Neurology Minute that is relevant to AAN interests or activities.
Margarita Fedorova, MD (Electric Gardens)	Dr. Fedorova has nothing to disclose.
Neil Nero, MLIS	Mr. Nero has nothing to disclose.
Ken Uchino, MD (Cleveland Clinic Foundation)	Dr. Uchino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aboott Laboratories, Inc.. Dr. Uchino has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ACP JOURNAL CLUB. The institution of Dr. Uchino has received research support from NIH.
Shumei Man, MD, PhD (Neurological Institute, Cleveland Clinic)	No disclosure on file